Format

Send to

Choose Destination
JACC Basic Transl Sci. 2017 Apr;2(2):122-131. doi: 10.1016/j.jacbts.2016.12.001. Epub 2016 Dec 19.

Cardiac Myosin Binding Protein-C Autoantibodies are Potential Early Indicators of Cardiac Dysfunction and Patient Outcome in Acute Coronary Syndrome.

Author information

1
Department of Cell and Molecular Physiology, Loyola University Chicago, Maywood, IL 60153, USA.
2
Clinical Research Office, Health Sciences Division, Loyola University Chicago, Maywood, IL 60153, USA.
3
Division of Cardiology, Scott and White Hospital, Texas A&M HSC College of Medicine, Temple, TX 76508, USA.
4
Hypertrophic Cardiomyopathy Clinic, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109-5644, USA.
5
Molecular Cardiology Research Institute, Center for Translational Genomics, Department of Medicine, Cardiology Division, Tufts Medical Center, Boston, MA 02111, USA.
6
Center for Cardiovascular Genetics, Institute of Molecular Medicine, Department of Medicine, University of Texas Health Sciences Center at Houston and Texas Heart Institute, Houston, TX 77030, USA.
7
Kerckhoff Heart and Thorax Center, Department of Cardiology, Bad Nauheim, Germany and DZHK (German Centre for Cardiovascular Research), partner site RheinMain, Frankfurt am Main, Germany.
8
Deparment of Cardiology and.
9
Department of Genetics, Harvard Medical School, Boston, MA 02115, USA.
10
Department of Physiology, Institute for Cardiovascular Research, VU University Medical Center, de Boelelaan 1108, 1081 HZ Amsterdam, The Netherlands.

Abstract

The degradation and release of cardiac myosin binding protein-C (cMyBP-C) upon cardiac damage may stimulate an inflammatory response and autoantibody (AAb) production. We determined whether the presence of cMyBP-C-AAbs associated with adverse cardiac function in CVD patients. Importantly, cMyBP-C-AAbs were significantly detected in ACS patient sera upon arrival to the emergency department, particularly in STEMI patients. Patients positive for cMyBP-C-AAbs had a reduced LVEF and elevated levels of clinical biomarkers of MI. We conclude that cMyBP-C-AAbs may serve as early predictive indicators of deteriorating cardiac function and patient outcome in ACS patients prior to the infarction.

KEYWORDS:

Acute myocardial infarction; Autoantibodies; Cardiac myosin binding protein-C; Cardiomyopathy

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center